Arsenic trioxide and all-trans retinoic acid suppress the expression of FLT3-ITD.

Leukemia & Lymphoma
Cong LiangXue-Qun Luo

Abstract

The prognosis of patients with acute myeloid leukemia (AML) caused by the FLT3-ITD mutation is poor. Arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) can down-regulate FLT3-ITD level and selectively kill leukemia cells carrying the FLT3-ITD mutation. However, the mechanisms of action of these two compounds are unknown. Here, we found that ATO could bind FLT3-ITD at Lys91 and Asp225, whereas ATRA could bind FLT3-ITD at Lys5 and Gln6. Both compounds could not bind wild-type FLT3. Further studies revealed that ATO/ATRA may suppress the Expression of FLT3-ITD by promoting the UBE2L6-mediated ubiquitination pathway and decreasing the expression of C-MYC. However, further studies are needed to define the mechanisms of these compounds on AML. Our research provides an experimental basis for the use of ATO/ATRA in FLT3-ITD AML in clinical practice.

References

Aug 17, 2006·Blood·Soheil MeshinchiJerald P Radich
Feb 20, 2009·Proceedings of the National Academy of Sciences of the United States of America·Jiong HuZhu Chen
Oct 5, 2011·Blood·Anna StaffasUNKNOWN Nordic Society of Pediatric Hematology and Oncology (NOPHO)
Dec 18, 2013·The Journal of Experimental Medicine·Guilherme Augusto Dos SantosPier Paolo Pandolfi
May 2, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Nadia ColtellaRosa Bernardi
Dec 2, 2015·Nature Reviews. Clinical Oncology·Catherine C CoombsRoss L Levine

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.